Paper21079425
Adverse events with isoniazid preventive therapy: experience from a large trial.
Grant AD and 5 others. AIDS, 2010. Cited by 40 papers, by iCite.
Cite this record
ConductScience Library. Adverse events with isoniazid preventive therapy: experience from a large trial. Papers, record 21079425. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21079425
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| AIDS-Related Opportunistic Infections | Major topic |
| Antitubercular Agents | Major topic |
| HIV Infections | Major topic |
| Isoniazid | Major topic |
| Tuberculosis | Major topic |
| Adult | |
| Female | |
| Humans | |
| Male | |
| Mining | |
| Prevalence | |
| Radiography, Thoracic | |
| South Africa |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Department of Health | United Kingdom | PubMed |
Source PubMed
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41550517 | Safety and Effectiveness of Long-Term Isoniazid Treatment for the Prevention of Tuberculosis in High-Risk Dialysis Patients. | Kidney Int Rep | 2026 | https://conductscience.org/library/papers/41550517 | PubMed |
| 41259110 | Adverse Drug Reactions Related to Isoniazid Preventive Therapy Among Persons Living With HIV on Dolutegravir-Based Regimens in Uganda Between July 2019 and March 2020. | J Acquir Immune Defic Syndr | 2026 | https://conductscience.org/library/papers/41259110 | PubMed |
| 39945250 | Latent Tuberculosis Screening and Active Tuberculosis Disease Development in People Living with HIV: A Multicenter Retrospective Cohort Study in Turkiye. | Curr HIV Res | 2025 | https://conductscience.org/library/papers/39945250 | PubMed |
| 39364056 | Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39364056 | PubMed |
| 37289412 | Liver Injury Following Isoniazid Preventive Therapy in HIV Patients Attending Halibet National Referral Hospital, Eritrea: A Prospective Cohort Study. | Drugs Real World Outcomes | 2023 | https://conductscience.org/library/papers/37289412 | PubMed |
| 35777873 | Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial. | BMJ Open | 2022 | https://conductscience.org/library/papers/35777873 | PubMed |
| 32875123 | Tuberculosis preventive therapy (TPT) to prevent tuberculosis co-infection among adults with HIV-associated cryptococcal meningitis: A clinician's perspective. | J Clin Tuberc Other Mycobact Dis | 2020 | https://conductscience.org/library/papers/32875123 | PubMed |
| 30758779 | Tolerability of Isoniazid Preventive Therapy in an HIV-Infected Cohort of Paediatric and Adolescent Patients on Antiretroviral Therapy from a Resource-Limited Setting: A Retrospective Cohort Study. | Drugs Real World Outcomes | 2019 | https://conductscience.org/library/papers/30758779 | PubMed |
| 30073087 | Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea. | Pharmacol Res Perspect | 2018 | https://conductscience.org/library/papers/30073087 | PubMed |
| 29692453 | Controversies in the Management of Cutaneous Adverse Drug Reactions. | Indian J Dermatol | 2018 | https://conductscience.org/library/papers/29692453 | PubMed |
| 29471904 | Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi. | Int J Tuberc Lung Dis | 2018 | https://conductscience.org/library/papers/29471904 | PubMed |
| 28775944 | Routine implementation of isoniazid preventive therapy in HIV-infected patients in seven pilot sites in Zimbabwe. | Public Health Action | 2017 | https://conductscience.org/library/papers/28775944 | PubMed |
| 28147705 | "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa. | AIDS Care | 2017 | https://conductscience.org/library/papers/28147705 | PubMed |
| 27695679 | Dotting the Three I's for collaborative TB-HIV activities: evaluation of a pilot programme in Kathmandu, Nepal. | Public Health Action | 2016 | https://conductscience.org/library/papers/27695679 | PubMed |
| 27516382 | Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. | Clin Infect Dis | 2016 | https://conductscience.org/library/papers/27516382 | PubMed |
| 26323809 | Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial. | J Neurovirol | 2016 | https://conductscience.org/library/papers/26323809 | PubMed |
| 26221405 | Successful diagnosis of hyperpyrexia induced by isoniazid in a child with suspected extra-pulmonary tuberculosis. | Int J Clin Exp Med | 2015 | https://conductscience.org/library/papers/26221405 | PubMed |
| 25700378 | Monitoring toxicity in individuals receiving treatment for latent tuberculosis infection: a systematic review versus expert opinion. | Eur Respir J | 2015 | https://conductscience.org/library/papers/25700378 | PubMed |
| 24957052 | Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study. | BMC Pharmacol Toxicol | 2014 | https://conductscience.org/library/papers/24957052 | PubMed |
| 24527412 | Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management. | Asia Pac Allergy | 2014 | https://conductscience.org/library/papers/24527412 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21079425
GET https://conductscience.org/api/papers/v1/21079425/cited_by?page=2